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Background: The mutation in KRAS exon 2 is a validated biomarker of resistance to anti-epidermal growth factor
receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Several reports have confirmed associations of
other RAS mutations with resistance to anti-EGFR therapy. However, the impact of BRAF and PIK3CA mutations on
the efficacy of anti-EGFR therapy remains controversial. Little is known about the frequencies and clinicopathological
features of these mutations, as well as the therapeutic effects of anti-EGFR therapy in mCRC patients with these
mutations, especially in the Asian population.
Methods: In this retrospective observational study, frequencies and clinicopathological features of KRAS, NRAS,
BRAF and PIK3CA mutations were evaluated in patients with mCRC. Among patients treated with anti-EGFR therapy,
objective response, progression-free survival (PFS), and overall survival (OS) were evaluated according to gene status.
Results: Among 264 patients, mutations in KRAS exon 2, KRAS exons 3 or 4, NRAS, BRAF and PIK3CA were detected in
34.1%, 3.8%, 4.2%, 5.4% and 6.4%, respectively. Thus, a total of 12.1% of patients without KRAS exon 2 mutations had
other RAS mutations. Primary rectal tumors tended to be more frequently observed in RAS mutant tumors. BRAF
mutations were more frequently observed with right-sided colon, poorly differentiated or mucinous adenocarcinoma,
and peritoneal metastasis. Among the 66 patients with KRAS exon 2 wild-type tumors treated with anti-EGFR agents,
PFS (5.8 vs. 2.2 months) and OS (17.7 vs. 5.2 months) were significantly better in patients with all wild-type tumors (n = 56)
than in those with any of the mutations (n = 10). The response rate also tended to be better with all wild-type tumors
(26.8 vs. 0%).
Conclusion: Other RAS and BRAF mutations were observed in KRAS exon 2 wild-type tumors, which were associated with
some clinicopathological features and resistance to anti-EGFR therapy in our patient cohort.
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Colorectal cancer was the third most common cancer in
men (746,000 cases, 10.0% of the total) and the second
in women (614,000 cases, 9.2% of the total) worldwide
in 2012 [1]. Mutations in KRAS exon 2 occur in ~35% of
all metastatic colorectal cancers (mCRCs) [2,3], and con-
stitutively activate the mitogen-activated protein kinase
(MAPK) pathway [4,5]. These mutations are validated
biomarkers for resistance to anti-epidermal growth factor
receptor (EGFR) therapy in patients with mCRC [6-11].
Although conventional KRAS tests are useful to exclude
patients without benefit from anti-EGFR therapy, response
rates and disease control rates to anti-EGFR antibody
monotherapy among patients with KRAS exon 2 wild-type
tumors are only 13–17% and 51%, respectively [6,7].
Therefore, more accurate patient selection requires identi-
fication of other predictive factors to improve the risk–
benefit profile of anti-EGFR therapy.
Until recently, there have been no validated bio-
markers other than KRAS exon 2 mutations. Recently,
several reports have shown that other KRAS (exons 3 or
4) and NRAS mutations (exons 2– 4) occur in ~20% of
mCRC patients with KRAS exon 2 wild-type tumors,
which are associated with resistance to anti-EGFR therapy
for mCRC [12-18].
BRAF mutations were detected in 5–10% of patients
with mCRC with V600E as a hot spot. BRAF is a down-
stream molecule of KRAS and the clinical data suggest
that BRAF V600E mutations are associated with poor
prognosis in patients with mCRC [11,12,19-24]. How-
ever, the relationship between BRAF mutations and the
efficacy of anti-EGFR therapy remains controversial
[19-22]. Besides the KRAS–BRAF pathway, the other
major downstream signaling pathway activated by EGFR
is the PI3K–AKT signaling pathway. PIK3CA mutations,
most of which were in exons 9 and 20, were detected in
10–15% of patients with mCRC. According to a European
Consortium report [19], PIK3CA mutations in exon 20
but not in exon 9 were associated with resistance to anti-
EGFR therapy for mCRC. However, in other studies, no
clear correlation between PIK3CA mutations and the effi-
cacy of anti-EGFR therapy has been observed [21,22].
Meanwhile, targeting agents for these mutations are under
development.
We previously reported that a multi-gene cancer panel
with Luminex technology (GENOSEARCH Mu-PACK,
MBL, Japan) is useful for detection of 36 mutations in
KRAS exons 3 or 4, NRAS, BRAF and PIK3CA in a single
reaction using 50-ng template DNA from formalin-fixed,
paraffin-embedded (FFPE) specimens [25]. Importantly, the
analysis of 82 samples was fully concordant with conven-
tional direct sequencing. However, information about the
frequencies and clinicopathological features of these muta-
tions in clinical practice, including the relationship betweenmutation status and the efficacy of anti-EGFR therapy, es-
pecially among Asian populations, is still limited.
In the present study, we evaluated the frequencies
andclinicopathological features of KRAS, NRAS, BRAF
and PIK3CA mutations in Japanese mCRC patients, and




We have conducted a retrospective observational study in
our institution to evaluate the frequencies and clinicopatho-
logical features of KRAS, NRAS, BRAF and PIK3CA muta-
tions in Japanese mCRC patients. Principal inclusion
criteria were as follows: histologically confirmed adenocar-
cinoma of the colon or rectum; and presence of unresect-
able metastatic disease.
Between January 2013 and June 2014, we analyzed 264
patients with mCRC who met the inclusion criteria. The
study was conducted with the approval of the National
Cancer Center Institutional Review Board. Written in-
formed consent was obtained from as many patients as
possible. For the deceased patients and their relatives,
we also disclosed the study design at the website of
National Cancer Center and gave them the opportunity
to express their wills in accordance with the Epidemio-
logical Study Guideline of Ministry of Health, Labour
and Welfare in Japan.
Molecular profiling and data analysis
Genomic DNA was extracted from FFPE cancer speci-
mens (239 primary tumors and 25 metastases). A total
of 36 mutations were analyzed using Luminex (xMAP)
technology (GENOSEARCH Mu-PACK, MBL), includ-
ing: KRAS codon 61 (Q61K, Q61E, Q61L, Q61P, Q61R
and Q61H); KRAS codon 146 (A146T, A146S, A146P,
A146E, A146V and A146G); NRAS codon 12 (G12S,
G12C, G12R, G12D, G12V and G12A), codon 13 (G13S,
G13C, G13R, G13D, G13V and G13A); codon 61 (Q61K,
Q61E, Q61L, Q61P, Q61R and Q61H); BRAF codon 600
(V600E); PIK3CA exon 9 codon 542 (E542K); codon 545
(E545K); codon 546 (E546K); and exon 20 codon 1047
(H1047R, H1047L). The lower limit of the percentage of
mutant allele in the tumor samples accepted by the
study was 5%. Initially, 50-ng samples of template DNA
were collected from FFPE tissue samples and were amp-
lified using polymerase chain reactions (PCRs) with a
biotin-labeled primer. Subsequently, PCR products and
fluorescent Luminex beads were bound to oligonucleo-
tide probes that were complementary to wild-type and
mutant genes, and were hybridized and labeled with
streptavidin–phycoerythrin. Subsequently, the products
were processed according to Luminex assays and data
were analyzed using UniMAG software (MBL). The
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dons 12 and 13) was evaluated by amplification using a
refractory mutation system–Scorpion assay with 1% sen-
sitivity in a central vendor laboratory.
Patient characteristics, including age, sex, site of primary
lesion, histology, site of metastases, and treatment results,
were collected from medical records. Sites of primary le-
sions were divided into right colon, left colon, and rectum.
Right-sided tumors were defined as those arising anywhere
from the cecum to the transverse colon, and left-sided tu-
mors as those arising anywhere from the splenic flexure to
the rectosigmoid junction. The efficacy of anti-EGFR ther-
apy was evaluated according to gene status in patients who
met the following inclusion criteria: Eastern Cooperative
Oncology Group performance status (ECOG PS) score ≤ 2,
KRAS exon 2 wild type, at least one prior chemotherapy
regimen, treatment with anti-EGFR either as monotherapy
or in combination with irinotecan or FOLFIRI (5-FU, L-
leucovorin and irinotecan), baseline computed tomography
(CT) performed within 28 days of anti-EGFR therapy, initial
evaluation of treatment effect via CT scan within 3 months
of initial anti-EGFR therapy and adequate hematological,
hepatic and renal function.
Statistical methods
Gene mutation frequencies and associations of RAS or
BRAF mutations with clinicopathological features were
estimated in mCRC patients.
Response rate (RR) and disease control rate (DCR; in-
cluding complete or partial response and stable disease)
were evaluated for anti-EGFR therapy according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST; ver-
sion 1.1). Progression-free survival (PFS) was defined as
the time from initial administration of anti-EGFR regimens
until the first objective evidence of disease progression orTable 1 Patient characteristics and clinicopathological feature
Characteristics All patients All RAS
(n = 264, %) (n = 15
Age Median (range) 64 (32–86) 64 (32–
Gender Male 166 (62.9) 94 (61.4
Primary lesion Right-sided colon 53 (20.1) 29 (19.0
Left-sided colon 70 (26.5) 50 (32.7
Rectum 141 (53.4) 74 (48.3
Histology Well, mod 240 (90.9) 133 (86
Por, muc 24 (9.1) 20 (13.1
Site of metastasis Liver 137 (51.2) 73 (47.7
Lung 100 (37.9) 55 (35.9
Lymph node 150 (56.8) 87 (56.9
Peritoneum 52 (19.7) 33 (21.6
*Kruskal–Wallis test; **χ2 or Fisher exact test. aany mutations in KRAS codons 61 or
mucinous carcinoma; por: poorly differentiated adenocarcinoma; well: well-differentdeath from any cause. Overall survival (OS) was defined as
the time from initial administration of anti-EGFR regimens
until death from any cause. For PFS or OS, patients were
censored at the time of their last follow-up if they were free
of disease progression or alive, respectively. PFS and OS
rates were estimated using the Kaplan–Meier method, and
differences among the groups according to KRAS, NRAS,
BRAF and PIK3CA gene status were identified by univari-
ate and multivariate analyses using Cox proportional haz-
ards models and presented as hazard ratios (HRs) with
95% confidence intervals (CIs). Confounders in univariate
and multivariate analyses included ECOG PS (0 vs. 1 and
2), numbers of metastatic sites (1 vs. ≥ 2), treatment line of
anti-EGFR regimens (2nd vs. 3rd) and types of anti-EGFR
regimens (monotherapy vs. combination therapy).
The χ2 test, Fisher’s exact test, Mann–Whitney U test,
or Kruskal–Wallis test was used to compare patient
characteristics and treatment response, as appropriate.
Statistical analyses were performed using IBM SPSS Sta-
tistics version 21 (IBM Corporation, Armonk, NY, USA).
All tests were two-sided, and differences were consid-
ered significant when P was < 0.05.
Results
Frequencies of KRAS, NRAS, BRAF and PIK3CA mutations
in mCRC patients
Patient characteristics and frequencies of gene mutations
in 264 patients are shown in Tables 1 and 2, respectively.
One hundred and thirty-three patients (50.1%) had tumors
with no mutation (all wild type). Mutations in KRAS co-
dons 12 or 13, KRAS codons 61 or 146 and NRAS codons
12, 13, or 61 were detected in 90 (34.1%), 10 (3.8%) and 11
(4.2%) patients, respectively. Fourteen (5.4%) patients had
BRAF codon 600 mutations, and 17 (6.4%) had PIK3CA
mutations (13 in exon 9 and 4 in exon 20). The genotypess according to RAS mutations
WT KRAS exon2 MT Any other RAS MTa P value
3, %) (n = 90, %) (n = 21, %)
82) 64 (38–82) 68 (48–86) 0.32*
) 56 (62.2) 16 (76.2) 0.41**
) 21 (23.3) 3 (14.3) 0.08**
) 15 (16.7) 5 (23.8)
) 54 (60.0) 13 (61.9)
.9) 88 (97.8) 19 (90.5) 0.17**
) 2 (2.2) 2 (9.5)
) 49 (54.4) 15 (71.4) 0.10**
) 40 (44.4) 5 (23.8) 0.16**
) 49 (54.4) 14 (66.7) 0.59**
) 15 (16.7) 4 (19.0) 0.64**
146 or NRAS. mod: moderately differentiated; MT: mutation type; muc:
iated adenocarcinoma; WT: wild type.
Table 2 Mutation rates of each gene in 264 mCRC
patients
Gene Wild type Mutation type Mutation
rate (%)
KRAS codon 12,13 174 90 34.1
KRAS codon 61, 146 254 10 3.8
NRAS codon 12, 13, 61 253 11 4.2
BRAF codon 600 250 14 5.4
PIK3CA exon 9, 20 247 17 6.4
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Additional file 1. All mutations were mutually exclusive ex-
cept for those in PIK3CA, and 21 (12.1%) patients without
KRAS mutations in exon 2 had other RAS mutations in ei-
ther KRAS exons 3 or 4 or NRAS exons 2 or 3 (Figure 1).
Association of RAS and BRAF mutations with
clinicopathological features
We analyzed the correlation between RAS or BRAF geno-
types and the clinicopathological features of mCRC. Pri-
mary rectal tumor tended to be more frequently observed
in KRAS exon 2 and other RAS mutant tumors than in
RAS wild-type tumors (60.0 vs. 61.9 vs. 48.3%, P = 0.08)
(Table 1), although this was not statistically significant.
BRAF mutant tumors were more likely to develop in the
right colon (57.1 vs. 18.0%, P = 0.001), and to have poorly
differentiated or mucinous adenocarcinoma (42.9 vs. 7.2%,
P = 0.001), and peritoneal metastasis (50.0 vs. 18.0%, P =
0.009) in comparison with BRAF wild-type tumors
(Table 3).
Efficacy of anti-EGFR therapies according to gene status
Patient characteristics
Between January 2013 and June 2014, 66 patients who
met the inclusion criteria were treated with second- andFigure 1 Associations between KRAS, NRAS, BRAF and PIK3CA mutations. Al
and NRAS were mutually exclusive. Mutations in PIK3CA exons 9 and 20 ovethird-line regimens containing anti-EGFR agents. Fifty-six
patients had tumors with no mutations (all wild-type tu-
mors) and 10 had tumors with mutation in either KRAS
codons 61 or 146, NRAS, BRAF, or PIK3CA (any of the
mutations). Among the 10 patients with any of the muta-
tions, three had KRAS codon 146 mutations, two had
NRAS mutations, two had BRAF mutations, two had
PIK3CA mutations (1 in exon 9 and 1 in exon 20), and
one had BRAF and PIK3CA exon 9 mutations (Table 4).
Patients with any of the mutations were more likely
to have worse PS and to be treated with anti-EGFR
monotherapy than combination in comparison with all
wild-type tumors. No other significant difference was
seen between the two groups (Table 4).
Response to treatment
Among patients with all wild-type tumors (n = 56),
complete response, partial response, stable disease and
progressive disease were observed in 0 (0%), 15 (26.8%),
29 (51.8%) and 12 (21.4%) patients, respectively. In con-
trast, among patients with any of the mutations (n = 10),
complete response, partial response, stable disease and
disease progression were observed in 0 (0%), 0 (0%), 5
(50.0%) and 5 (50.0%) patients, respectively. Thus, RR of
patients with all wild-type tumors (n = 56) and those
with any of the mutations (n = 10) were 26.8% and 0%
(P = 0.101), respectively. Although DCR did not differ
significantly between the two groups (78.6 vs. 50.0%, P =
0.109), DCR with complete or partial response and
stable disease after > 3 months was significantly better in
patients with all wild-type tumors than in those with any
of the mutations (76.8 vs. 10%, P = 0.019).
Among the 10 patients with mutations, three were
treated with second-line anti-EGFR-containing regimens
and seven were treated with third-line regimens. All three
patients treated with second-line anti-EGFR therapy werel mutations in KRAS codons 12 and 13, KRAS codons 61 and 146, BRAF
rlapped with those in KRAS codons 12 and 13 and BRAF.
Table 3 Clinicopathological features according to BRAF mutations
Characteristics BRAF WT BRAF MT P value
(n = 250, %) (n = 14, %)
Age Median (range) 64 (32-86) 64 (46-75) 0.53*
Gender Male 160 (64.0) 6 (42.9) 0.15**
Primary lesion Right-sided colon 45 (18.0) 8 (57.1) 0.001**
Left-sided colon 67 (26.8) 3 (21.4)
Rectum 138 (55.2) 3 (21.4)
Histology Well, mod 232 (92.8) 8 (57.1) 0.001**
Por, muc 18 (7.2) 6 (42.9)
Site of metastasis Liver 131 (52.4) 6 (42.9) 0.58**
Lung 97 (38.8) 3 (21.4) 0.26**
Lymph node 143 (57.2) 7 (50.0) 0.59**
Peritoneum 45 (18.0) 7 (50.0) 0.009
*Mann–Whitney U test; **χ2 or Fisher exact test.
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was treated with irinotecan plus panitumumab and
showed stable disease after > 3 months. In contrast, all
seven patients treated with third-line anti-EGFR therapy
were irinotecan refractory and only two had stable disease
at < 3 months.
Survival analysis
The median PFS of patients with any of the mutations









Number of metastasis 1
>2




Gene mutation KRAS codon 61, 146
NRAS codon12, 13, 61
PIK3CA exon 9, 20
BRAF codon 600
*Mann–Whitney U test; **χ2 or Fisher exact test. aWild type KRAS codons 61, 146, NR
PIK3CA. mab: monoclonal antibody.significantly shorter than that of patients with all wild-type
tumors (n = 56; 5.8 months; 95% CI, 4.8–6.7 months),
as verified in both univariate (HR 3.38; 95% CI, 1.65–
6.93; P = 0.001) and multivariate analyses (HR 2.77; 95%
CI, 1.16–6.61; P = 0.021) (Figure 2A, Table 5).
The median OS of patients with any of the mutations
(n = 10; 5.2 months; 95% CI, 3.8–6.6 months) was signifi-
cantly shorter than that of patients with all wild-type tu-
mors (n = 56; 17.7 months; 95% CI, 1.1–34.3 months), as
verified in both univariate (HR 4.94; 95% CI, 2.12–11.5;erapy
All WTa Any MTb P value
(n = 56, %) (n = 10, %)
64 (34–79) 64 (51–74) 0.629*
38 (67.9) 3 (30.0) 0.034**
18 (32.1) 7 (70.0)
35 (62.5) 5 (50.0) 0.498**
21 (37.5) 5 (50.0)
53 (94.6) 8 (80.0) 0.162**
3 (5.4) 2 (20.0)
14 (25.0) 4 (40.0) 0.442**
42 (75.0) 6 (60.0)
27 (48.2) 3 (30.0) 0.327**
29 (51.8) 7 (70.0)
44 (78.6) 3 (30.0) 0.004**





AS, BRAF and PIK3CA; bany mutations in KRAS codons 61 or 146, NRAS, BRAF or
Figure 2 Kaplan–Meier plots of PFS and OS according to KRAS, NRAS, BRAF and PIK3CA gene status. A) The median PFS was 5.8 months (95% CI,
4.8–6.7) among patients with all wild-type tumors (n = 56) and was 2.2 months (1.9–2.5) among those with mutations in KRAS codons 61 or 146,
BRAF, NRAS or PIK3CA (n = 10). Differences in PFS between patients with all wild-type tumors and those with mutations in KRAS codons 61 or 146,
BRAF, NRAS, or PIK3CA were statistically significant (HR, 3.38; 95% CI, 1.65–6.93; P = 0.001). B) The median OS was 17.7 months (95% CI, 1.1–34.3)
among patients with all wild-type tumors (n = 56) and was 5.2 months (3.8–6.6) among those with mutations in KRAS codons 61 or 146, BRAF,
NRAS or PIK3CA (n = 10). Differences in OS values between patients with all wild-type tumors and those with mutations in KRAS codons 61 or 146,
BRAF, NRAS or PIK3CA were statistically significant (HR, 4.94; 95% CI, 2.12–11.5; P < 0.001).
Kawazoe et al. BMC Cancer  (2015) 15:258 Page 6 of 9P < 0.001) and multivariate analyses (HR 3.38; 95% CI,
1.19–9.58; P = 0.022) (Figure 2B, Table 5).
Discussion
We elucidated the prevalence of KRAS, NRAS, BRAF
and PIK3CA mutations in Japanese mCRC patients, and
clarified the relationship between gene status and clini-
copathological features, including the efficacy of anti-
EGFR therapy. To date, clinical evidence about these
mutations in mCRC has been based on clinical studies
in western countries. The present study is believed to be
the first to provide information on frequency and type of
KRAS, NRAS, BRAF and PIK3CA mutations in Japanese
patients with mCRC. In addition, the clinical feasibility
of the present novel multiplex kit was demonstrated.
In our patient cohort, the frequency of patients with
KRAS exon 2 (34.1%) mutant tumors was similar to that
in previous studies [2-4]. A total of 12.1% of patients
without KRAS exon 2 mutations had other RAS mutations,
which was lower than that in recent studies from western
countries, which showed 15–26% of these mutations
[12-18]. Another previous study from Japan showed that
other RAS mutations were detected in seven (12.7%) of 55
samples without KRAS exon 2 mutations with 3–13% sen-
sitivity [26], which was similar to our result. Several possible
explanations for the relatively lower frequency of other RAS
mutations in our study compared with western studies
might be considered. First, there were some differences indetectable RAS mutations by multiplex kit between our
study and western studies. In our study, we did not analyze
KRAS codons 59 and 117 and NRAS codons 59, 117 and
146, while these codons were analyzed in most western
studies. Although the frequencies of these mutations are
considered to be low, it might be one of the causes of the
lower frequency in our patient cohort. Second, the sensitiv-
ity of RAS mutation analysis may vary among studies. In
the present study, all mutations were detectable with 5–
10% sensitivity. In contrast, Surveyor Scan Kits, BEAMing
technology and pyrosequencing were used in pivotal stud-
ies, and RAS mutations were detected with 1–10% sensitiv-
ity [12-18]. A recent multicenter study in Japan, including
our institution, showed that other RAS mutations were de-
tected in 15% of patients with KRAS exon 2 wild type, using
a newer multiplex kit (MEBGEN RASKET Kit) [27]. This
method detected 48 RAS mutations in exon 2 (codons 12
and 13), exon 3 (codons 59 and 61) and exon 4 (codons
117 and 146), with 1–5% sensitivity in a single reaction
using 50–100-ng DNA from FFPE tissue without manual
dissection. Given these methodological differences, further
studies are required to confirm differences in the preva-
lence of other RAS mutations between Asian and western
populations. In this study, we detected BRAF mutations in
5.4% of patients. The prevalence of BRAF mutation might
be dependent on the patient population studied. mCRC pa-
tients with BRAF mutant tumors have a poor prognosis, so
the prevalence of BRAF mutant populations may decline in
Table 5 Univariate and multivariate analyses of PFS and OS
Variables No mPFS
(months)
Univariate analysis Multivariate analysis mOS
(months)
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Mutation status All WT 56 5.8 reference - reference - 17.7 reference - reference -
Any MT 10 2.2 3.38 (1.65–6.93) 0.001 2.77 (1.16–6.61) 0.021 5.2 4.94 (2.12–11.5) <0.001 3.38 (1.19–9.58) 0.022
ECOG PS 0 41 6.0 reference - reference - 31.3 reference - reference -
1-2 25 3.5 2.82 (1.53–5.20) 0.001 1.80 (0.89–3.64) 0.101 9.7 3.41 (1.52–7.69) 0.003 1.62 (0.59–4.42) 0.346
Number of metastasis 1 18 6.0 reference - reference - 15.4 reference - reference -
>2 48 5.1 1.57 (0.82–3.00) 0.17 1.51 (0.73–3.11) 0.268 16.7 1.70 (0.68–4.29) 0.257 1.60 (0.59–4.30) 0.353
Treatment line of anti-EGFR mab 2nd 30 7.6 reference - reference - 17.7 reference - reference -
3rd 36 4.0 1.85 (1.06–3.25) 0.032 1.52 (0.83–2.79) 0.174 15.9 1.43 (0.66–3.10) 0.367 0.97 (0.41–2.29) 0.940
Combination therapy Yes 47 7.4 reference - reference - 31.3 reference - reference -
No 19 2.6 4.82 (2.49–9.35) <0.001 2.73 (1.28–5.83) 0.009 10.5 3.31 (1.48–7.41) 0.004 2.03 (0.83–4.96) 0.121
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The prevalence of BRAF mutations in our patient cohort
was similar to that of previous studies of pretreated patients
with mCRC [11,12,19-24].
We also investigated the clinicopathological features of
mCRC patients with respect to RAS and BRAF muta-
tions. Primary rectal tumor tends to be more frequently
observed in KRAS exon 2 and other RAS mutant tumors
rather than RAS wild-type tumors, although this was not
statistically significant. Previous studies showed that
KRAS exon 2 mutation was significantly higher in the
right colon [28,29], in disagreement with our analysis.
No significant differences in other clinicopathological
features such as age, sex, primary lesion, histology, and
site of metastasis were observed between KRAS exon 2
and other RAS mutant tumors, which is similar to previ-
ous studies [30]. Regardless of these clinicopathological
features, it is reported that other gene expression pro-
files based on The Cancer Genome Atlas appear to be
similar in patients with KRAS and NRAS mutant mCRC,
suggesting that treatment selection based on molecular
profile is important [30]. In accordance with previous re-
ports [23,24], BRAF mutant tumors are more likely to
develop in the right colon, and to have poorly differenti-
ated or mucinous adenocarcinoma, and peritoneal me-
tastasis in comparison with BRAF wild-type tumors.
In agreement with previous studies [19,25], mutations in
KRAS exons 3 or 4, NRAS, BRAF or PIK3CA were not as-
sociated with clinical benefits from anti-EGFR therapy in
the present cohort. On the basis of recent prospective and
retrospective randomized trials of anti-EGFR therapy
[12-18], the National Comprehensive Cancer Network
(NCCN) recommends anti-EGFR therapy for mCRC pa-
tients without other RAS mutant tumors or KRAS exon 2
mutant tumors [31]. The Japanese Society of Medical
Oncology (JSMO) also recommends testing for all RAS
mutations in patients with mCRC before anti-EGFR ther-
apy. In contrast, whether BRAF and PIK3CA mutations are
predictive of the efficacy of anti-EGFR therapy remains
controversial [19-22]. Previous trials suggest that intensive
combination chemotherapy with FOLFOXIRI (5-FU, L-
leucovorin, irinotecan, and oxaliplatin) and bevacizumab
might be especially effective for BRAF mutant mCRC [32].
Recently, the combination of BRAF inhibitors and anti-
EGFR monoclonal antibodies, with or without PI3K inhibi-
tors or MEK inhibitors, has shown promising results in
phase I trials in patients with BRAF mutant CRC [33,34].
Patients with BRAF mutant CRC are often refractory to
systematic chemotherapy and have poor prognosis, there-
fore, screening for BRAF mutations is important during
recruitment of patients for these clinical trials. Accordingly,
we conducted a multi-institutional screening (GI-SCREEN)
study using the present multiplex kit to elucidate the na-
tionwide prevalence of these targetable mutations.There were several methodological limitations to the
present study. First, not all of the patients in our study
period were evaluated for their RAS gene status. Thus,
the analysis may have been subject to some selection
bias. Second, the small sample size and single-center
population were other major limitations. Owing to the
overall small number of patients with KRAS exon 3 or 4,
NRAS, BRAF or PIK3CA mutations, we could not evalu-
ate the impact of each gene mutation on the efficacy of
anti-EGFR therapy. In addition, our analyses were ex-
plorative and hypothesis generating. This issue should
be analyzed in a larger cohort.
Conclusions
Other RAS and BRAF mutations have been observed in
KRAS exon 2 wild-type tumors, which were associated
with some clinicopathological features and resistance to
anti-EGFR therapy in our patient cohort. Importantly,
because there are a certain number of mCRC patients
with molecular alteration other than KRAS exon 2, further
refinement of tumor-specific genetic markers is needed to
improve the efficacy of anti-EGFR therapy.
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